Skip to main content
. 2022 Jan 7;23(2):646. doi: 10.3390/ijms23020646

Figure 1.

Figure 1

(A): Experimental design for the treatment with recombinant AZGP1 (rAZGP1) after UUO. (B): AZGP1 levels in serum of untreated mice without surgery and untreated and treated mice 14 days after UUO. (C): Lotus tetragonolobus lectin (LTL) staining and Picrosirius Red staining after 14 days UUO. (D). Quantification of LTL staining. (E): Quantification of Picrosirius Red staining. (F–H): Damage and fibrosis marker mRNA expression after 14 days UUO. Significance was tested by student’s t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.